Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients ...

In a major new study, researchers from Intermountain Health in Salt Lake City have found that weight loss drugs used by ...

The startup is advancing a drug licensed from China’s Hengrui Pharma that it claims could be “best-in-class” among a group of ...

With $185 million in series A funding and an army of experienced leaders in its ranks, Braveheart Bio is setting off to joust ...

During an AHA press conference, Li explained that each component of the triple-receptor agonist compensates for side effects ...

Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...

In a large real-world analysis across three U.S. healthcare databases, semaglutide and tirzepatide showed cardiovascular benefits consistent with randomized trials. Semaglutide lowered heart attack ...

Amgen's Repatha lowered first heart attacks and strokes by 36% in a major trial, suggesting PCSK9 drugs may prevent acute ...

Major news in the women’s health world today: the Food and Drug Administration (FDA) just announced that it recommends drug ...